Fluorosalan

Fluorosalan (5 pM-38 μM; 5 h) inhibits the transcriptional activity of NF-κB in TNF-α- and IL-1β-induced NF-κB-bla ME180 human cervical cancer cells, with IC₅₀ values of 7.9 μM and 24.4 μM, respectively^[1].
Fluorosalan (5 h) inhibits TNF-α-induced NF-κB transcriptional activity in NF-κB-luc2P HEK293 human embryonic kidney cells, with an IC₅₀ of 25.3 μM^[1].
Fluorosalan (30 min) inhibits TNF-α-induced phosphorylation of IκBα at serine-32 in GFP-IκBα GripTite HEK293 cells, with an IC₅₀ of 2.8 μM^[1].
Fluorosalan (10 μM; 1 h) reduces TNF-α-induced phosphorylation of IκBα at serine-32 in IkB HEK293 cells^[1].
Fluorosalan (5-24 h) does not induce caspase 3/7 activity in NF-κB-bla ME180 human cervical cancer cells^[1].
Fluorosalan (24 h) depolarizes the mitochondrial membrane potential of ME180 human cervical cancer cells, with an IC₅₀ of 1.2 μM^[1].
Fluorosalan (5-72 h) inhibits the viability of ME180 human cervical cancer cells, with IC₅₀ values of 9.0 μM (24 h), 2.7 μM (48 h) and 1.3 μM (72 h)^[1].
Fluorosalan (5-72 h) inhibits the viability of human cervical cancer HeLa cells, with IC₅₀ values of 3.1 μM (24 h), 2.1 μM (48 h) and 3.3 μM (72 h)^[1].
Fluorosalan binds to the human IκBα/NF-κB complex (PDB ID: 1IKN) with a maximum binding energy of -8.5 kcal/mol, suggesting that it has potential inhibitory activity against the NF-κB signaling pathway^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.